ω-3 fatty acid treatment in multiple sclerosis (OFAMS study): A randomized, double-blind, placebo-controlled trial

Archives of Neurology

Volumn 69, Issue 8, 2012, Pages 1044-1051

  Torkildsen, Øivind ^a   Wergeland, Stig ^a   Bakke, Søren ^c   Beiske, Antonie G ^f   Bjerve, Kristian S ^g,h   Hovdal, Harald ^g   Midgard, Rune ⁱ   Lilleås, Finn ^d   Pedersen, Tom ^j   Bjørnarå, Bård ^k   Dalene, Frøydis ^l   Kleveland, Grethe ^m   Schepel, Jan ⁿ   Olsen, Inge Christoffer ^e   Myhr, Kjell Morten ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d Curato Oslo   (Norway)

^e Smerud Medical Research International   (Norway)

^f MS Senteret Hakadal AS   (Norway)

^g TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^h NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

ⁱ Molde Hospital   (Norway)

^j Unilabs   (France)

^k Helsehuset Kongsberg   (Norway)

^l TELEMARK HOSPITAL   (Norway)

^m Lillehammer Hospital   (Norway)

ⁿ HAUGESUND HOSPITAL   (Norway)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GADOLINIUM; OMEGA 3 FATTY ACID; PLACEBO; TRIOMAR; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADULT; ADVERSE OUTCOME; ALLERGIC REACTION; ARTHRALGIA; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DOUBLE BLIND PROCEDURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAIR LOSS; HEADACHE; HUMAN; INJECTION SITE REACTION; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYALGIA; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; PATIENT SAFETY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RELAPSE; SCORING SYSTEM; SHORT FORM 36; URINARY TRACT INFECTION;

ADULT; DIETARY SUPPLEMENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FATTY ACIDS, OMEGA-3; FEMALE; HUMANS; INTERFERON-BETA; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS; TREATMENT OUTCOME;

EID: 84865643296     PISSN: 00039942     EISSN: 15383687     Source Type: Journal    
DOI: 10.1001/archneurol.2012.283     Document Type: Article

References (31)

1. Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502- 1517.
2. Jacobs LD, Cookfair DL, Rudick RA, et al The Multiple Sclerosis Collaborative Research Group (MSCRG). Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol. 1996;39(3):285-294. (Pubitemid 26100751)
3. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. the Copolymer 1 Multiple Sclerosis Study Group. Neurology. 1995;45(7):1268-1276.
4. Kappos L, Bates D, Edan G, et al. Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. Lancet Neurol. 2011;10(8):745-758.
5. Paty DW, Li DK; UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis, II: MRI analysis results of a multicenter, randomized, double-blind, placebocontrolled trial. Neurology. 1993;43(4):662-667. (Pubitemid 23121952)
6. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Randomised double-blind placebocontrolled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet. 1998;352(9139):1498-1504.
7. Mehta LR, Dworkin RH, Schwid SR. Polyunsaturated fatty acids and their potential therapeutic role in multiple sclerosis. Nat Clin Pract Neurol. 2009;5(2): 82-92.
8. Bates D, Cartlidge NE, French JM, et al. A double-blind controlled trial of long chain n-3 polyunsaturated fatty acids in the treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry. 1989;52(1):18-22. (Pubitemid 19043864)
9. Weinstock-Guttman B, Baier M, Park Y, et al. Low fat dietary intervention with omega-3 fatty acid supplementation in multiple sclerosis patients. Prostaglandins Leukot Essent Fatty Acids. 2005;73(5):397-404. (Pubitemid 41375637)
10. Schwarz S, Knorr C, Geiger H, Flachenecker P. Complementary and alternative medicine for multiple sclerosis. Mult Scler. 2008;14(8):1113-1119.
11. Stewart TM, Bowling AC. Polyunsaturated fatty acid supplementation in MS. Int MS J. 2005;12(3):88-93.
12. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001;50(1):121-127.
13. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology. 1983;33(11):1444-1452. (Pubitemid 14237132)
14. Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol. 1989;46(10):1121-1123. (Pubitemid 19246303)
15. Ware JE, Snow KK, Kosinksi M, Gandek B. SF-36 Health Survey: Manual & Interpretation Guide. Boston, MA: The Health Institute, New England Medical Center; 1997.
16. Cutter GR, Baier ML, Rudick RA, et al. Development of a multiple sclerosis functional composite as a clinical trial outcome measure. Brain. 1999;122(pt 5): 871-882. (Pubitemid 29219261)
17. Filippi M, Rovaris M, Capra R, et al. A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis: implications for phase II clinical trials. Brain. 1998;121(pt 10):2011-2020. (Pubitemid 28454367)
18. Andersen RK. Statistical Models Based on Counting Processes. New York, NY: Springer; 1993.
19. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. JAm Stat Assoc. 1989;84(408):1074-1078. doi:10.2307/2290085.
20. Ghadirian P, Jain M, Ducic S, Shatenstein B, Morisset R. Nutritional factors in the aetiology of multiple sclerosis: a case-control study in Montreal, Canada. Int J Epidemiol. 1998;27(5):845-852. (Pubitemid 28504973)
21. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand. 2000;102(3): 143-149. (Pubitemid 30645133)
22. Sormani MP, Miller DH, Comi G, et al. Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. J Neurol Neurosurg Psychiatry. 2001;70(4):494-499. (Pubitemid 32269687)
23. Carney RM, Freedland KE, Rubin EH, Rich MW, Steinmeyer BC, Harris WS. Omega-3 augmentation of sertraline in treatment of depression in patients with coronary heart disease: a randomized controlled trial. JAMA. 2009;302(15): 1651-1657.
24. Smith GI, Atherton P, Reeds DN, et al. Dietary omega-3 fatty acid supplementation increases the rate of muscle protein synthesis in older adults: a randomized controlled trial. Am J Clin Nutr. 2011;93(2):402-412.
25. Bates D, Fawcett PR, Shaw DA, Weightman D. Trail of polyunsaturated fatty acids in non-relapsing multiple sclerosis. Br Med J. 1977;2(6092):932-933. (Pubitemid 8191255)
26. Millar JH, Zilkha KJ, Langman MJ, et al. Double-blind trial of linoleate supplementation of the diet in multiple sclerosis. Br Med J. 1973;1(5856):765-768.
27. Paty DW. Double-blind trial of linoleic acid in multiple sclerosis. Arch Neurol. 1983;40(11):693-694. (Pubitemid 13022425)
28. Brunelleschi S, Bardelli C, Amoruso A, et al. Minor polar compounds extravirgin olive oil extract (MPC-OOE) inhibits NF-kappa B translocation in human monocyte/macrophages. Pharmacol Res. 2007;56(6):542-549. (Pubitemid 350137776)
29. Bates D, Fawcett PR, Shaw DA, Weightman D. Polyunsaturated fatty acids in treatment of acute remitting multiple sclerosis. Br Med J. 1978;2(6149):1390- 1391. (Pubitemid 9048723)
30. Paty DW, Cousin HK, Read S, Adlakha K. Linoleic acid in multiple sclerosis: failure to show any therapeutic benefit. Acta Neurol Scand. 1978;58(1):53-58. (Pubitemid 9030732)
31. Farinotti M, Simi S, Di Pietrantonj C, et al. Dietary interventions for multiple sclerosis. Cochrane Database Syst Rev. 2007;(1):CD004192.